Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
93 hedge funds and large institutions have $155M invested in Poseida Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 22 reducing their positions, and 12 closing their positions.
656% more call options, than puts
Call options by funds: $1.32M | Put options by funds: $175K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
73% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 22
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
2% more funds holding
Funds holding: 91 → 93 (+2)
8% less capital invested
Capital invested by funds: $169M → $155M (-$13.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$814K |
| 2 |
State Street
Boston,
Massachusetts
|
+$604K |
| 3 |
William Blair & Company
Chicago,
Illinois
|
+$373K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$357K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$265K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$774K |
| 2 |
AI
Atom Investors
Austin,
Texas
|
-$612K |
| 3 |
Jane Street
New York
|
-$604K |
| 4 |
Morgan Stanley
New York
|
-$288K |
| 5 |
AGP
Artia Global Partners
Miami,
Florida
|
-$274K |
PSTX Hedge Fund Activity: Q2 2024 in Review
93 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q2 2024, worth a combined $155M — down 8.1% from $169M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new PSTX positions and 12 closed out — a net gain of 2 holders — while 38 added to existing stakes and 22 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $814K. The largest seller was Connor, Clark & Lunn Investment Management (CC&L), cutting an estimated $774K.
- 93 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q2 2024, up from 91 in Q1 2024.
- Funds reported $155M of Poseida Therapeutics, Inc. Common Stock stock for Q2 2024, down 8.1% quarter-over-quarter.
- 14 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q2 2024 and 12 closed out, a net change of +2 holders.
- The largest Poseida Therapeutics, Inc. Common Stock buyer in Q2 2024 was Renaissance Technologies, an estimated $814K added.
- The largest Poseida Therapeutics, Inc. Common Stock seller in Q2 2024 was Connor, Clark & Lunn Investment Management (CC&L), an estimated $774K sold.
Based on aggregated 13F filings for Q2 2024.